Drug safety evaluation of adefovir in HBV infection

Expert Opinion on Drug Safety

Volumn 10, Issue 5, 2011, Pages 809-818

  Viganò, Mauro ^b   Lampertico, Pietro ^a   Colombo, Massimo ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b San Giuseppe Hospital   (Italy)

Author keywords

adefovir dipivoxil; chronic hepatitis B; creatinine; creatinine clearance; hepatitis B virus; kidney; nucleotide analog; renal impairment; safety

Indexed keywords

ADEFOVIR DIPIVOXIL; EMTRICITABINE; PLACEBO;

ARTICLE; BONE DENSITY; CREATININE CLEARANCE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; FANCONI RENOTUBULAR SYNDROME; HEPATITIS B; HUMAN; HYPOPHOSPHATEMIA; MAXIMUM PLASMA CONCENTRATION; NEPHROTOXICITY; PHASE 4 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADENINE; ANTIVIRAL AGENTS; CLINICAL TRIALS, PHASE III AS TOPIC; HEPATITIS B, CHRONIC; HUMANS; PHOSPHONIC ACIDS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 80051999959     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2011.593507     Document Type: Article

References (58)

1. Keeffe EB, Zeuzem S, Koff RS, et al. Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin Gastroenterol Hepatol 2007;5:890-7 A roadmap concept based on HBV DNA monitoring optimizes treatment outcomes in HBV patients.
2. Lok ASF, McMahon BJ. Chronic hepatitis B: Update 2009. Hepatology 2009;10:661-2
3. Fontana RJ. Side effects of long-term oral antiviral therapy for hepatitis B. Hepatology 2009;49:S185-95 A detailed and recent review that summarizes the safety profile of NUC for the treatment of chronic hepatitis B patients.
4. Hepsera prescribing information. Gilead Sciences, Inc.; 2002; p. 1-18
5. Dando TM, Plosker GL. Adefovir dipivoxil a review of its use in chronic hepatitis B. Drugs 2003;63:2215-34
6. Knight W, Hayashi S, Benhamou Y, et al. Dosing guidelines for adefovir in the treatment of chronic hepatitis B patients with renal or hepatic impairment. J Hepatol 2003;38:A308
7. Shiffman ML, Pol S, Rostaing L, et al. Efficacy and pharmacokinetics of adefovir dipivoxil liquid suspension in patients with chronic hepatitis B and renal impairment. J Clin Pharmacol 2010; [Epub ahead of print]
8. Ono-Nita SK, Kato N, Shiratori Y, et al. Susceptibility of lamivudine-resistant hepatitis B virus to other reverse transcriptase inhibitors. J Clin Invest 1999;102:1635-40
9. Xiong X, Flores C, Yang H, et al. Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro. Hepatology 1998;28:1669-73
10. Fisher EJ, Chaloner K, Cohn DL, et al. Community programs for clinical research on AIDS: The safety and efficacy of adefovir dipivoxil in patients with adefovir dipivoxil and HIV disease: A randomized, placebo controlled trial. AIDS 2001;15:1695-700
11. Kahn J, Lagakos S, Wulfsohn M, et al. Efficacy and safety of adefovir dipivoxil with antiretroviral therapy: A randomized controlled trial. JAMA 1999;282:2305-12
12. Jeffers L, Heathcote E, Wright T, et al. A phase II dose-ranging, placebo-controlled trial of adefovir dipivoxil for the treatment of chronic hepatitis B virus infection. Antiviral Res 1998;37:A197
13. Marcellin P, Chang TT, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003;348:808-16 The favorable risk:benefit profile of ADV monotherapy in HBeAg-positive patients resulting in histologic liver improvement, HBV DNA reduction and high rates of HBeAg seroconversion.
14. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Adefovir dipivoxil 438 study group. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003;348:800-7
15. Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008;359:2442-55 A double-blind, Phase III study comparing 48-week treatment with tenofovir and ADV on HBeAg-negative or -positive CHB patients.
16. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006;131:1743-51
17. Benhamou Y, Bochet M, Thibault V, et al. Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: An open-label pilot study. Lancet 2001;358:718-23
18. Perrillo R, Hann HW, Mutimer D, et al. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology 2004;126:81-90
19. Peters MG, Hann Hw H, Martin P, et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 2004;126:91-101
20. Schiff ER, Lai CL, Hadziyannis S, et al. Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in preand post-liver transplantation patients. Hepatology 2003;38:1419-27
21. Schiff E, Lai CL, Hadziyannis S, et al. Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: Final long-term results. Liver Transpl 2007;13:349-60
22. European Association for the Study of the Liver. EASL Clinical practice guidelines: Management of chronic hepatitis B. J Hepatol 2009;50:227-42 The most recent and updated guidelines for the management of patients with chronic hepatitis B.
23. Tanji N, Tanji K, Kambham N, et al. Adefovir nephrotoxicity: Possible role of mitochondrial DNA depletion. Hum Pathol 2001;32:734-40
24. Imaoka T, Kusuhara H, Adachi M, et al. Functional involvement of multidrug resistance-associated protein 4 in the renal elimination of the antiviral drugs adefovir and tenofovir. Mol Pharmacol 2007;71:619-27
25. Cihlar T, Lin DC, Pritchard JB, et al. The antiviral nucleotide analogs cidofovir and adefovir are novel substrates for human and rat renal organic anion transporter 1. Mol Pharmacol 1999;56:570-80
26. Miller DS. Nucleoside phosphonate interactions with multiple organic anion transporters in renal proximal tubule. J Pharmacol Exp Ther 2001;299:567-74
27. Izzedine H, Launay-Vacher V, Deray G. Antiviral drug-induced nephrotoxicity. Am J Kidney Dis 2005;45:804-17
28. Schuetz JD, Connelly MC, Sun D, et al. MRP4: A previously unidentified factor in resistance to nucleoside-based antiviral drugs. Nat Med 1999;5:1048-51
29. Wijnholds J, Mol CA, van Deemter L, et al. Multidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs. Proc Natl Acad Sci USA 2000;97:7476-81
30. Vigano M, Lampertico P, Dongiovanni P, et al. A drug transporter gene polymorphism predicts renal tubular toxicity in patients with chronic hepatitis B on long-term adefovir and lamivudine combination. J Hepatol 2010;52:S7
31. Izzedine H, Hulot JS, Launay-Vacher V, et al. Renal safety of adefovir dipivoxil in patients with chronic hepatitis B: Two double-blind, randomized, placebo-controlled studies. Kidney Int 2004;66:1153-8
32. Marcellin P, Chang TT, Lim SG, et al. Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2008;48:750-8
33. Zeng M, Mao Y, Yao G, et al. A double-blind randomized trial of adefovir dipivoxil in Chinese subjects with HBeAg-positive chronic hepatitis B. Hepatology 2006;44:108-16
34. Ha NB, Ha NB, Garcia RT, et al. Renal dysfunction in chronic hepatitis B patients treated with adefovir dipivoxil. Hepatology 2009;50:727-34
35. Sung JJ, Lai JY, Zeuzem S, et al. Lamivudine compared with lamivudine and adefovir for the treatment of HBeAg positive chronic hepatitis B. J Hepatol 2008;48:728-35
36. Hui CK, Zhang HY, Bowden S, et al. 96 weeks combination of adefovir dipivoxil plus emtricitabine vs adefovir dipivoxil monotherapy in the treatment of chronic hepatitis B. J Hepatol 2008;48:714-20
37. Wursthorn K, Lutgehetmann M, Dandri M, et al. Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology 2006;44:675-84
38. Piccolo P, Lenci I, Demelia L, et al. A randomized controlled trial of pegylated interferon-alpha2a plus adefovir dipivoxil for hepatitis B e antigen-negative chronic hepatitis B. Antivir Ther 2009;14:1165-74
39. Perrillo R, Schiff E, Yoshida E, et al. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology 2000;32:129-34
40. Lampertico P, Vigano M, Manenti E, et al. Low resistance to adefovir combined with lamivudine: A 3-year study of 145 lamivudine resistant hepatitis B patients. Gastroenterology 2007;133:1445-51 3 years of adefovir plus lamivudine combination therapy in LMV-R patients suppressed HBV replication in most patients, preventing virologic and clinical breakthrough.
41. Rapti I, Dimou E, Mitsoula P, et al. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology 2007;45:307-13
42. Yatsuji H, Suzuki F, Sezaki H, et al. Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: Two-year follow-up. J Hepatol 2008;48:923-31
43. Tamori A, Enomoto M, Kobayashi S, et al. Add-on combination therapy with adefovir dipivoxil induces renal impairment in patients with lamivudine-refractory hepatitis B virus. J Viral Hepat 2010;17:123-9 The first report of Fanconi syndrome in a HBV mono-infected, lamivudine-resistant patient exposed to ADV + LMV for 3 years.
44. Vigano M, Lampertico P, Iavarone M, et al. High risk of renal impairment and arterial hypertension during long-term adefovir and lamivudine combination therapy in patients with lamivudine-resistant chronic hepatitis B. Hepatology 2008;48:708A
45. Lee JM, Park JY, Kim Do Y, et al. Long-term adefovir dipivoxil monotherapy for up to 5 years in lamivudine-resistant chronic hepatitis B. Antivir Ther 2010;15:235-41 A large cohort of 320 Korean, lamivudine-resistant patients receiving ADV monotherapy for up to 5 years.
46. Zoulim F, Parvaz P, Marcellin P, et al. Adefovir dipivoxil is effective for the treatment of cirrhotic patients with lamivudine failure. Liver Int 2009;29:420-6
47. Liaw Y-F, Raptopoulou-Gigi M, Cheinquer H, et al. Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with evidence of hepatic decompensation. Hepatology 2009;50:505A
48. Fontaine H, Vallet-Pichard A, Chaix ML, et al. Efficacy and safety of adefovir dipivoxil in kidney recipients, hemodialysis patients, and patients with renal insufficiency. Transplantation 2005;80:1086-92
49. de Silva HJ, Dassanayake AS, Manamperi A, et al. Treatment of lamivudine-resistant hepatitis B infection in post-renal transplant patients with adefovir dipivoxil: Preliminary results. Transplant Proc 2006;38:3118-20
50. Kamar N, Huart A, Tack I, et al. Renal side effects of adefovir in hepatitis B virus-(HBV) positive kidney allograft recipients. Clin Nephrol 2009;71:36-42
51. Tse KC, Yap DY, Tang CS, et al. Response to adefovir or entecavir in renal allograft recipients with hepatitic flare due to lamivudine-resistant hepatitis B. Clin Transplant 2010;24:207-12
52. Tillmann HL, Bock CT, Bleck JS, et al. Successful treatment of fibrosing cholestatic hepatitis using adefovir dipivoxil in a patient with cirrhosis and renal insufficiency. Liver Transpl 2003;9:191-6
53. Gornals JB, Casanovas T, Sabido M, et al. Clinical and virological effects during two years of ongoing adefovir dipivoxil in the treatment of lamivudine-resistant chronic hepatitis B infection. Transplant Proc 2005;37:3957-9
54. Jonas MM, Kelly D, Pollack H, et al. Safety, efficacy, and pharmacokinetics of adefovir dipivoxil in children and adolescents (age 2 to
55. Izzedine H, Kheder-Elfekih R, Housset P, et al. Adefovir dipivoxil-induced acute tubular necrosis and Fanconi syndrome in a renal transplant patient. AIDS 2009;23:544-5
56. Jung YK, Yeon JE, Choi JH, et al. Fanconi's syndrome associated with prolonged adefovir dipivoxil therapy in a hepatitis B virus patient. Gut Liver 2010;4:389-93
57. Girgis CM, Wong T, Ngu MC, et al. Hypophosphataemic osteomalacia in patients on adefovir dipivoxil. J Clin Gastroenterol 2011;45:468-73
58. Vigano M, Lampertico P, Eller-Vainicher C, et al. High prevalence of reduced bone mineral density in patients with chronic hepatitis B under nucleos(t)ides analogues treatment. Hepatology 2010;52:526A